Abstract | BACKGROUND: Better biomarkers must be found to develop clinically useful urine tests for bladder cancer. Proteomics can be used to identify the proteins released by cancer cell lines and generate candidate markers for developing such tests. METHODS: RESULTS:
Bladder cancer cell lines shed soluble EGFR ectodomain. Soluble EGFR is also detectable in urine and is highly elevated in some patients with high-grade bladder cancer. Urinary EGFR is an independent indicator of poor bladder cancer-specific survival with a hazard ratio of 2.89 (95% CI 1.81-4.62, P<0.001). In multivariable models including both urinary EGFR and EpCAM, both biomarkers are predictive of bladder cancer-specific survival and have prognostic value over and above that provided by standard clinical observations. CONCLUSIONS: Measuring urinary EGFR and EpCAM may represent a simple and useful approach for fast-tracking the investigation and treatment of patients with the most aggressive bladder cancers.
|
Authors | R T Bryan, H L Regan, S J Pirrie, A J Devall, K K Cheng, M P Zeegers, N D James, M A Knowles, D G Ward |
Journal | British journal of cancer
(Br J Cancer)
Vol. 112
Issue 6
Pg. 1052-8
(Mar 17 2015)
ISSN: 1532-1827 [Electronic] England |
PMID | 25719831
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antigens, Neoplasm
- Biomarkers, Tumor
- Cell Adhesion Molecules
- EPCAM protein, human
- Epithelial Cell Adhesion Molecule
- EGFR protein, human
- ErbB Receptors
|
Topics |
- Aged
- Aged, 80 and over
- Antigens, Neoplasm
(urine)
- Biomarkers, Tumor
(urine)
- Case-Control Studies
- Cell Adhesion Molecules
(urine)
- Cell Line, Tumor
- Epithelial Cell Adhesion Molecule
- ErbB Receptors
(urine)
- Female
- Humans
- Male
- Prognosis
- Urinary Bladder Neoplasms
(diagnosis, urine)
|